PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics chief technical operations officer Neil Gregory Almstead received new equity awards in the company. On January 2, 2026 he was granted 17,500 restricted stock units that vest in four equal annual installments starting January 2, 2027. He also indirectly holds 6,956 shares of common stock through his spouse, including 520 shares from this grant and 257 shares acquired under the employee stock purchase plan for the period ended December 31, 2025.
In addition, he received a stock option for 43,750 shares of common stock at an exercise price of $76.74 per share. This option was granted on January 2, 2026 and vests over four years, with 25% vesting on January 2, 2027 and a further 6.25% of the original shares vesting at the end of each successive three‑month period beginning April 2, 2027. After these transactions he beneficially owns 118,382 shares directly and the 6,956 shares indirectly.
PTC Therapeutics director Jerome B. Zeldis reported new equity awards from the company. On January 2, 2026, he received 4,000 shares of common stock in the form of restricted stock units, bringing his directly held common shares to 22,500. These RSUs vest over one year, with five-twelfths vesting on June 2, 2026 and the remaining seven-twelfths on January 2, 2027. He has elected to defer receipt of all vested shares until the earliest of four years from grant, six months after separation of service, a change in control event, or death.
On the same date, he was also granted a stock option for 3,475 shares of common stock with an exercise price of $76.74 per share. This option vests in twelve equal monthly installments over one year starting February 2, 2026 and expires on January 1, 2036.
PTC Therapeutics director Stephanie Okey reported new equity awards. On January 2, 2026, she received 4,000 shares of common stock as restricted stock units at a grant price of $0, increasing her directly held common stock to 12,000 shares after the transaction.
The restricted stock units vest over one year, with five-twelfths of the underlying shares vesting on June 2, 2026 and the remaining seven-twelfths vesting on January 2, 2027. She was also granted a stock option for 3,475 shares of common stock at an exercise price of $76.74 per share and a grant price of $0, vesting in twelve equal monthly installments starting February 2, 2026. Following this grant, she directly holds 3,475 stock options.
PTC Therapeutics director Michael Schmertzler reported new equity awards. On January 2, 2026 he received 8,000 shares of common stock in the form of restricted stock units at a price of $0, increasing his directly held common stock to 163,266 shares. The RSUs vest over one year, with five-twelfths vesting on June 2, 2026 and the remaining seven-twelfths vesting on January 2, 2027.
He was also granted a stock option for 6,950 shares of common stock with an exercise price of $76.74 per share. This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments starting on February 2, 2026. Both awards are reported as directly owned by Schmertzler.
PTC Therapeutics chief financial officer Pierre Gravier reported new equity awards. On January 2, 2026, he received 20,000 restricted stock units, which vest in four equal annual installments starting on January 2, 2027. His direct holdings of common stock totaled 92,449 shares after this grant, including shares previously acquired through the company’s employee stock purchase plan.
On the same date, he was also granted a stock option for 50,000 shares of common stock with an exercise price of $76.74 per share and an expiration date of January 1, 2036. This option vests over four years, with 25% vesting on January 2, 2027 and an additional 6.25% of the original grant vesting at the end of each successive three-month period beginning April 2, 2027.
PTC Therapeutics insider Matthew Klein has filed a Rule 144 notice to sell 5,149 shares of common stock. The planned sale is to be executed through Fidelity Brokerage Services, with an aggregate market value of $396,203.19, and an approximate sale date of January 6, 2026 on NASDAQ. The shares to be sold were acquired on January 5, 2026 through restricted stock vesting as compensation from the issuer.
PTC Therapeutics had 80,288,305 shares of common stock outstanding. Over the prior three months, Matthew Klein sold 3,428 shares for gross proceeds of $271,062.93 on December 2, 2025, and 8,089 shares for $619,921.55 on December 30, 2025. By signing, the seller represents they are not aware of undisclosed material adverse information about the company’s operations.
A holder of common shares of symbol PTCT has filed a Form 144 notice for a planned sale of 1,381 shares through Fidelity Brokerage Services on the NASDAQ. The filing lists an aggregate market value of $106,264.64 for these shares and notes that there were 80,288,305 shares outstanding at the time of the notice. The shares to be sold were acquired on 01/05/2026 through restricted stock vesting from the issuer as compensation, with payment also dated 01/05/2026.
A holder of PTCT common stock has filed a Form 144 notice to sell 1,739 common shares. The shares are planned to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 01/06/2026. The filing notes an aggregate market value for this block of $133,811.88 and shows 80,288,305 common shares outstanding.
The 1,739 shares were acquired on 01/05/2026 via restricted stock vesting from the issuer as compensation. Over the past three months, the same seller, identified as Mark Boulding, has reported multiple sales of PTCT common stock, including transactions on 10/06/2025, 10/07/2025, 11/17/2025, and 01/05/2026 with disclosed gross proceeds for each sale.
An insider of the issuer filed a notice of proposed sale of 1,789 shares of common stock, to be sold through Fidelity Brokerage Services LLC on or about 01/06/2026, with the shares listed on NASDAQ. These shares were acquired on 01/05/2026 through restricted stock vesting from the issuer as compensation.
As context, the filing reports 80,288,305 common shares outstanding. Over the prior three months, Eric Pauwels reported selling common shares in three transactions totaling 40,290; 3,202; and 20,508 shares, for gross proceeds of $3,038,755.33, $240,354.49, and $1,584,387.54, respectively.
Neil G. Almstead filed a notice of proposed sale of 1,279 shares of common stock through Fidelity Brokerage Services LLC, with an approximate sale date of 01/06/2026 on NASDAQ. These shares were acquired as restricted stock vesting from the issuer on 01/05/2026 as compensation.
In the prior three months, Neil G. Almstead sold 35,572 common shares on 11/24/2025 for gross proceeds of 2,852,153.65 and 71,928 common shares on 11/25/2025 for gross proceeds of 6,001,524.59. The notice also includes a representation that he is not aware of undisclosed material adverse information about the issuer.